TA212 Colorectal cancer (metastatic) - bevacizumab: review decision - July 2013 information
History
A list of downloadable documents created during development.
Background information
-
-
TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix A decision paper presented to the Institute's Guidance Executive
-
-
TA212 Colorectal cancer (metastatic) - bevacizumab: review proposal - May 2013 information
-
TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix A - provisional matrix of stakeholders
-
-
TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive
-
Colorectal cancer (metastatic) - bevacizumab: Equality Impact Assessment form
-
Colorectal cancer (metastatic) - bevacizumab: Equality Impact Assessment form
-
Colorectal cancer (metastatic) - bevacizumab: Equality Impact Assessment form (PDF 68 KB)
Colorectal cancer (metastatic) - bevacizumab: final appraisal determination
-
Colorectal cancer (metastatic) - bevacizumab: final appraisal determination information
-
Colorectal cancer (metastatic) - bevacizumab: final appraisal determination
-
Colorectal cancer (metastatic) - bevacizumab: final appraisal determination (PDF 237 KB)
-
Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the ACD and comments from website consultation
-
Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the first ACD and comments from website consultation (Issued November 2009)
-
-
Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the second ACD and comments from website consultation (Issued August 2010)
-
-
Colorectal cancer (metastatic) - bevacizumab: ERG Additional Analyses - cost of oxaliplatin
-
-
Colorectal cancer (metastatic) - bevacizumab: consultee and commentator comments on the ACD
-
Colorectal cancer (metastatic) - bevacizumab: Roche
-
Colorectal cancer (metastatic) - bevacizumab: Roche (PDF 125 KB)
-
Colorectal cancer (metastatic) - bevacizumab: Bowel Cancer UK
-
Colorectal cancer (metastatic) - bevacizumab: Bowel Cancer UK (PDF 51 KB)
-
Colorectal cancer (metastatic) - bevacizumab: Royal College of Nursing
-
Colorectal cancer (metastatic) - bevacizumab: Royal College of Nursing (PDF 55 KB)
-
Colorectal cancer (metastatic) - bevacizumab: National Collaborating Centre for Cancer
-
Colorectal cancer (metastatic) - bevacizumab: National Collaborating Centre for Cancer (PDF 124 KB)
Colorectal cancer (metastatic) - bevacizumab: appraisal consultation
-
Colorectal cancer (metastatic) - bevacizumab: appraisal consultation
-
Colorectal cancer (metastatic) - bevacizumab: appraisal consultation document information
-
Colorectal cancer (metastatic) - bevacizumab: evaluation report
-
Colorectal cancer (metastatic) - bevacizumab: evidence review group response
-
Colorectal cancer (metastatic) - bevacizumab: evidence review group response (PDF 19 KB)
-
Colorectal cancer (metastatic) - bevacizumab: letter from the Department of Health information
-
Colorectal cancer (metastatic) - bevacizumab: letter from the Department of Health (PDF 24 KB)
-
Colorectal cancer (metastatic) - bevacizumab: critique by the evidence review group of the additional analyses and amended model provided by the manufacturers
-
-
-
Colorectal cancer (metastatic) - bevacizumab: PAS template
-
Colorectal cancer (metastatic) - bevacizumab: PAS template (PDF 112 KB)
-
Colorectal cancer (metastatic) - bevacizumab: draft fax back form
-
Colorectal cancer (metastatic) - bevacizumab: draft fax back form (PDF 29 KB)
-
Colorectal cancer (metastatic) - bevacizumab: PSA analysis submitted by Roche
-
Colorectal cancer (metastatic) - bevacizumab: PSA analysis submitted by Roche (PDF 27 KB)
-
Colorectal cancer (metastatic) - bevacizumab: response to ACD1 from consultees and commentators
-
Colorectal cancer (metastatic) - bevacizumab: Roche
-
Colorectal cancer (metastatic) - bevacizumab: ACD response
-
Colorectal cancer (metastatic) - bevacizumab: ACD response (PDF 115 KB)
-
Colorectal cancer (metastatic) - bevacizumab: operating costs
-
Colorectal cancer (metastatic) - bevacizumab: operating costs (PDF 48 KB)
-
Colorectal cancer (metastatic) - bevacizumab: time and motion results
-
Colorectal cancer (metastatic) - bevacizumab: time and motion results (PDF 105 KB)
-
Colorectal cancer (metastatic) - bevacizumab: administration costs
-
Colorectal cancer (metastatic) - bevacizumab: administration costs (PDF 90 KB)
-
Colorectal cancer (metastatic) - bevacizumab: Bowel Cancer UK
-
Colorectal cancer (metastatic) - bevacizumab: Bowel Cancer UK (PDF 78 KB)
Colorectal cancer (metastatic) - bevacizumab: appraisal consultation document
-
Colorectal cancer (metastatic) - bevacizumab: appraisal consultation document
-
Colorectal cancer (metastatic) - bevacizumab: appraisal consultation document information
-
Colorectal cancer (metastatic) - bevacizumab: evaluation report
-
Pre-meeting briefing
-
-
Evidence review group report
-
ERG report
-
-
ERG additional information
-
-
ERG additional analyses
-
-
Clarification
-
NICE Clarification letter
-
-
Response to clarification letter 1
-
-
Response to clarification letter 2
-
-
Response to clarification letter 3
-
-
Response to clarification letter 4
-
-
Non-manufacturer submissions
-
Royal College of Nursing
-
-
Royal College of Physicians
-
-
Bowel Cancer UK Submission
-
-
Beating bowel cancer submission
-
-
Manufacturer submission
-
Manufacturer submission
-
-
Manufacturer submission: appendix 1
-
-
Manufacturer submission: appendix 2
-
-
Manufacturer submission: appendix 3
-
-
Manufacturer submission: PAS template
-
-
Expert statement: Barbara Moss
-
Colorectal cancer (metastatic) - bevacizumab: final scope
-
Colorectal cancer (metastatic) - bevacizumab: final scope
-
Colorectal cancer (metastatic) - bevacizumab: final scope (PDF 27 KB)
Colorectal cancer (metastatic) - bevacizumab: final matrix of consultees and commentators
-
Colorectal cancer (metastatic) - bevacizumab: final matrix of consultees and commentators
-
Colorectal cancer (metastatic) - bevacizumab: response to comments on the draft scope
-
Colorectal cancer (metastatic) - bevacizumab: response to comments on the draft scope
-
Colorectal cancer (metastatic) - bevacizumab: response to comments on the draft scope (PDF 58 KB)
Colorectal cancer (metastatic) - bevacizumab: response to comments on the provisional matrix
-
Colorectal cancer (metastatic) - bevacizumab: response to comments on the provisional matrix
-
Colorectal cancer (metastatic) - bevacizumab: draft scope
-
Colorectal cancer (metastatic) - bevacizumab: draft scope
-
Colorectal cancer (metastatic) - bevacizumab: draft scope (PDF 34 KB)
Colorectal cancer (metastatic) - bevacizumab: provisional matrix of consultees and commentators - pre-referral
-
Colorectal cancer (metastatic) - bevacizumab: provisional matrix of consultees and commentators - pre-referral
-